Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13602345 | 0.80 | SLC9A1 (0.64) | SLC9A1 | |
| SCHEMBL8530219 | 0.78 | SLC9A1 (0.69) | SLC9A1 | |
| SCHEMBL1005550 | 0.77 | TDP1 (0.41) | — | |
| SCHEMBL8532554 | 0.76 | SLC9A1 (0.50) | SLC9A1 | |
| SCHEMBL13813413 | 0.76 | SLC9A1 (0.46) | SLC9A1 | |
| SCHEMBL8699590 | 0.75 | SLC9A1 (0.56) | SLC9A1 | |
| SCHEMBL8533153 | 0.71 | SLC9A1 (0.64) | SLC9A1 | |
| SCHEMBL14607348 | 0.71 | SLC9A1 (0.51) | SLC9A1 | |
| Hydrochloric Acid SCHEMBL8393812 | 0.70 | SLC9A1 (0.53) | SLC9A1 | |
| SCHEMBL1259969 | 0.70 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143473-A1 | USE OF INHIBITORS OF THE CELLULAR NA+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143473-A1 | USE OF INHIBITORS OF THE CELLULAR NA+/H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS | NHERF1, LIPG, SLC8B1 | SLC9A1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.